IL-6 and related cytokines as the critical lynchpins between inflammation and cancer

Highlights

• The IL-6 family of cytokines includes IL-6, IL-11, IL-27, IL-31, LIF, OSM, CNTF, CT-1 and CLC.

• The IL-6 family of cytokines regulates cell proliferation, survival, migration, invasion, metastasis, angiogenesis and inflammation via gp130.

• The JAK-STAT3 pathway is the major pathway downstream of gp130 signaling.

• IL-6 and IL-11 are highly up-regulated in many cancers and are important mediators linking inflammation and cancer.

• IL-6 and IL-11 are potential therapeutic and preventive targets as well as prognostic factors in cancer.

Abstract

Inflammatory responses play pivotal roles in cancer development, including tumor initiation, promotion, progression, and metastasis. Cytokines are now recognized as important mediators linking inflammation and cancer, and are therefore potential therapeutic and preventive targets as well as prognostic factors. The interleukin (IL)-6 family of cytokines, especially IL-6 and IL-11, is highly up-regulated in many cancers and considered as one of the most important cytokine families during tumorigenesis and metastasis. This review discusses molecular mechanisms linking the IL-6 cytokine family to solid malignancies and their treatment.

Introduction

Inflammatory responses play important roles in cancer development, including tumor initiation, promotion, progression, and metastasis [1], [2]. Inflammation also affects the immune surveillance of early cancer and responses to cancer therapy. At least 20% of all cancers arise in association with persistent infections and chronic inflammation, and even those cancers that do not develop as a consequence of chronic inflammation, exhibit extensive inflammatory infiltrates, referred to as ‘tumor-elicited inflammation’, with high cytokine expression in the tumor microenvironment [1], [3], [4].

Interleukin (IL)-6 is one of the best-characterized pro-tumorigenic cytokines. Its family members include IL-11, IL-27, IL-31, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) and cardiotrophin-like cytokine (CLC), all of which affect cell proliferation, survival, differentiation, migration, invasion, metastasis, angiogenesis, inflammation and metabolism [5] (Fig. 1). IL-6 family members, with the exception of IL-31, can activate the Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) pathway, the Src homology 2 (SH2)-containing protein tyrosine phosphatase-2 (SHP-2)-Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway and the phosphoinositide 3-kinase (PI3K)-Akt pathway through engagement of their unique receptor(s) and the common signaling receptor subunit glycoprotein 130 (gp130, CD130, IL6ST) [5], [6]. Among these pathways, STAT3 is recognized as the major signal transducer downstream of gp130 signaling because STAT3 functions as an oncogene and is a key player linking inflammation and cancer [6], [7], [8]. In addition to IL-6 family members, STAT3 can be activated by growth factor receptors, such as hepatocyte growth factor (HGF) receptor, c-MET and epidermal growth factor (EGF) receptor (EGFR) [9], [10], and Src family kinases (SFKs) [11]. It is assumed that different members of the IL-6 family activate similar signaling pathways, and the physiological specificity of cytokine action is mainly determined by the tissue specificity of ligand and receptor expression, magnitude and kinetic of their induction, and biological availability [12], [13]. Within the IL-6 family, IL-6 has been singled out for special attention because of its central role in physiological and pathological processes. Previous studies suggested that IL-6 is elevated in many cancers, including skin, breast, lung, esophageal, liver, pancreatic, gastric, colorectal, gynecological, prostate, kidney, bladder and hematological cancers as well as melanoma [14] (Table 1). IL-11 is also increased in several cancers, including breast, liver, pancreatic, gastric, colorectal, and prostate cancers as well as endometrial cancer [15] (Table 1).